市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Celcuity Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.4
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.38 |
|
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 13.21% |
| 机构持股比例 | 81.78% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Sio Capital Management, Llc | 30 Sep 2025 | 786,526 |
| Apis Capital Advisors, Llc | 30 Sep 2025 | 776,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 134.00 (Jefferies, 31.05%) | 购买 |
| 中 | 110.00 (7.58%) | |
| 低 | 70.00 (Needham, -31.54%) | 购买 |
| 平均值 | 108.14 (5.76%) | |
| 总计 | 6 购买, 1 保留 | |
| 平均价格@调整类型 | 89.88 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wells Fargo | 12 Dec 2025 | 126.00 (23.23%) | 购买 | 105.25 |
| Jefferies | 02 Dec 2025 | 134.00 (31.05%) | 购买 | 97.50 |
| Wolfe Research | 18 Nov 2025 | 110.00 (7.58%) | 购买 | 91.60 |
| HC Wainwright & Co. | 17 Nov 2025 | 94.00 (-8.07%) | 保留 | 92.23 |
| 22 Oct 2025 | 77.00 (-24.69%) | 购买 | 70.04 | |
| Craig-Hallum | 13 Nov 2025 | 108.00 (5.62%) | 购买 | 86.00 |
| Stifel | 13 Nov 2025 | 115.00 (12.47%) | 购买 | 86.00 |
| Needham | 20 Oct 2025 | 70.00 (-31.54%) | 购买 | 70.58 |
| 03 Oct 2025 | 70.00 (-31.54%) | 购买 | 50.51 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合